Biomerica, Inc. (NASDAQ: BMRA) shares were slightly down Thursday. The company, an innovator in diagnostic-guided therapy, today announced responder analysis results from its ongoing real-world study of inFoods® IBS. The data demonstrates that a majority of patients achieved clinically meaningful reductions in both abdominal pain and bloating—the two most debilitating symptoms of Irritable Bowel Syndrome (IBS).
The analysis was conducted on 69 patients who completed the full eight-week study protocol with both baseline and endpoint assessments. The FDA-recognized responder definition of =30% improvement in weekly average symptom scores was applied—the same endpoint used in the Company’s peer-reviewed randomized controlled trial (RCT) published in
Gastroenterology:
• Abdominal Pain: 59.4% of patients (41 of 69) met the responder threshold.
• Bloating: 68.1% of patients (47 of 69) met the responder threshold.
Among the 69 patients, 62 patients tested positive for one or more food sensitivities on the IBS-specific IgG assay:
• Mean abdominal pain scores decreased 34.6%, from 3.24 at baseline to 2.12 at 8 weeks (P = 0.0002).
These results validate the inFoods® IBS test in a real-world clinical setting using the same rigorous endpoints the FDA applies to clinical trials for IBS drug therapies, demonstrating clinical utility beyond controlled trial conditions.
BMRA shares doffed four cents, or 1.9%, to $2.12.
Related Stories
